A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity

Table 1 Demographic data and immunogenicity

	Vi-DT	Vi-PS
Gender
Males (%)	45	40
Females (%)	55	60
Mean age (years)	25.26	25.18
Seroconversion ≥ 4 times (%) at 28 days compared to baseline	100%	95.96%
Pre-vaccination GMT (IU/mL)	0.0226103	0.0048849
28 days post-vaccination GMT (IU/mL)	263.9313	51.72027

ISSN: 2055-0936